Subtype
Lung Non-Squamous Non-Small Cell Carcinoma
CI-CAN-00005826Explore in graph →
93 active trials5 approved drugs127 evidence items
- NCIt
- C135017
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005826Explore in graph →
Clinical trials
408 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (55)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05849246 | The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) | terminated | Phase 2 | 4 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Aug 20, 2024 | clinicaltrials |
| NCT04770688 | Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib(AUTOMAN) | completed | Phase 1 / Phase 2 | 25 | Shanghai Chest HospitalOTHER |
| 1 |
| Aug 15, 2024 |
| clinicaltrials |
| NCT04740047 | Cios Mobile 3D Spin for Robotic Bronchoscopy | completed | — | 38 | Mayo ClinicOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT02759835 | Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jun 7, 2024 | clinicaltrials |
| NCT06441357 | Differentiating the Invasiveness of Lung Adenocarcinoma by Dual Energy CT Parameter | unknown | — | 2,000 | Tang-Du HospitalOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05717803 | Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012) | recruiting | Phase 3 | 307 | Fudan UniversityOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT05266846 | Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK(BEYOND) | recruiting | Phase 2 | 78 | Hunan Province Tumor HospitalOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT05982574 | Tumor Microenvironment | active not recruiting | — | 300 | University Hospital HeidelbergOTHER | 0 | May 8, 2024 | clinicaltrials |
| NCT04027946 | LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Apr 16, 2024 | clinicaltrials |
| NCT03076164 | A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib | completed | Phase 1 / Phase 2 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06334757 | Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure | unknown | Phase 2 | 46 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06335355 | A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients | not yet recruiting | Phase 2 / Phase 3 | 401 | Shanghai Shengdi Pharmaceutical Co., LtdINDUSTRY | 1 | Mar 28, 2024 | clinicaltrials |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 127 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT04691375 | A Study of PY314 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 86 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT04310943 | Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma | completed | Phase 2 | 24 | Zhou ChengzhiOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT03190239 | Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer Patients(XQonc-007) | withdrawn | Phase 2 | 0 | Xinqiao Hospital of ChongqingOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06255197 | Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers | recruiting | — | 60,000 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT04046614 | Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology(NintNivo) | completed | Phase 1 / Phase 2 | 56 | AIO-Studien-gGmbHOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT05526573 | Diagnostic Yeld of Ultrathin Bronchoscopy in Peripheral Pulmonary Lesions | unknown | — | 148 | Azienda Sanitaria-Universitaria Integrata di UdineOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT03646968 | Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study(SAVE) | unknown | Phase 2 | 43 | Yongchang ZhangOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT05318443 | A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer | completed | Phase 3 | 512 | Shanghai Institute Of Biological ProductsINDUSTRY | 1 | Dec 27, 2023 | clinicaltrials |
| NCT04870034 | Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer | withdrawn | Early Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT06031181 | Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019) | recruiting | Phase 3 | 390 | Fudan UniversityOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT03802240 | Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure | completed | Phase 3 | 492 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Nov 27, 2023 | clinicaltrials |
| NCT06104709 | Local and Peripheral Immune Responsive Landscape Induced by Local Cryoablation in Patients With Lung Adenocarcinoma | unknown | — | 10 | China-Japan Friendship HospitalOTHER | 0 | Oct 27, 2023 | clinicaltrials |
| NCT05550961 | APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch | recruiting | — | 1,200 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT05498597 | AMT-151 in Patients With Selected Advanced Solid Tumours | unknown | Phase 1 | 30 | Multitude Therapeutics Inc.INDUSTRY | 2 | Oct 19, 2023 | clinicaltrials |
| NCT03468985 | Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer | completed | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT06056115 | Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic | recruiting | N/A | 20 | Hebei Medical University Fourth HospitalOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT06028633 | Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients | not yet recruiting | Phase 2 | 28 | Peking University First HospitalOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06031246 | Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018) | recruiting | Phase 3 | 634 | Fudan UniversityOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT05338619 | A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy(PLATINUM) | unknown | Phase 2 | 77 | Sung Yong LeeOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT05841472 | Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | recruiting | Phase 2 | 60 | CrystalGenomics, Inc.INDUSTRY | 1 | Aug 30, 2023 | clinicaltrials |
| NCT04012619 | Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer | completed | Phase 1 | 8 | Sichuan UniversityOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT04971187 | Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05962021 | Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation | unknown | Phase 2 | 126 | Peking University People's HospitalOTHER | 0 | Aug 1, 2023 | clinicaltrials |
| NCT05838053 | Comparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm | recruiting | — | 446 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT04959981 | A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC(HERKULES-2) | completed | Phase 1 | 24 | Erasca, Inc.INDUSTRY | 1 | Jul 25, 2023 | clinicaltrials |
| NCT05794711 | Intraoperative Frozen Section Pathology to Guide Surgical Treatment for Lung Adenocarcinoma (ECTOP-1015) | unknown | — | 1,063 | Fudan UniversityOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT05794724 | Intraoperative Frozen Section Pathology to Guide Surgical Treatment for Lung Adenocarcinoma (ECTOP-1016) | unknown | — | 1,063 | Fudan UniversityOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT04165759 | HRCT in Prediction of Tumor Invasion in GGO Lung Adenocarcinoma (ECTOP-1008) | completed | — | 620 | Fudan UniversityOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT05252676 | Evaluation of Correlations Between Radiologic Features and Pathologic Subtypes of GGO LUAD Via WMS (ECTOP-1011) | completed | — | 103 | Fudan UniversityOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT02980991 | Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma (ECTOP-1002) | completed | Phase 2 | 80 | Fudan UniversityOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT05527808 | A Single-arm Exploratory Study of Neoadjuvant Therapy | unknown | N/A | 28 | Jun LiuOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT00946712 | S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer | terminated | Phase 3 | 1,333 | SWOG Cancer Research NetworkNETWORK | 2 | May 23, 2023 | clinicaltrials |
| NCT02633189 | Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer(BEVERLY) | unknown | Phase 3 | 200 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT04396457 | Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901 | unknown | Phase 2 | 50 | National Hospital Organization Nagoya Medical CenterOTHER | 1 | Mar 23, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Aug 20, 2024source: clinicaltrials